Earnings Call · Q2 FY2022·2022-08-11

Q2 22EPS +53.76%·Rev n/aQ1 22EPS -6.32%·Rev n/aQ4 21EPS -20.00%·Rev n/aQ3 21EPS -6.06%·Rev n/a⚠ consensus missing

Spero Therapeutics, Inc. SPRO

Ted Jenkins — Investor Relations or Communications Officer

Ankit Mahadevia — Chief Executive Officer (CEO)

David Melnick — Executive or Medical/Clinical Officer

Sath Shukla — Chief Financial Officer (CFO)

−8.4%1d on move date−8.4% vs SPY3d+6.3%5d+25.9%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more SPRO calls or request research access.

More SPRO calls Browse calls Request research access